title: Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis.
abstract: BACKGROUND
  There are no treatments with established efficacy for this disorder so far.
  
  
  OBJECTIVE
  To systematically review the efficacy of acotiamide in the treatment of patients with FD.
  
  
  METHODS
  We searched main electronic databases through November 2013. RCTs evaluating the efficacy of acotiamide versus placebo in FD patients were included. Pooled risk ratio (RR) with 95% confidential interval (CI) was calculated.
  
  
  RESULTS
  Six publications including seven RCTs were eligible for inclusion. The summary RR of overall improvement of FD symptoms in patients receiving acotiamide versus placebo was 1.29 (95% CI, 1.19-1.40, P < 0.00001; I(2) = 15%). Acotiamide improved the symptoms of patients with postprandial distress syndrome (PDS) (RR, 1.29; 95% CI, 1.09-1.53, P = 0.003; I(2) = 0%), and the summary RR for patients with epigastric pain syndrome (EPS) was 0.92 (95% CI, 0.76-1.11, P = 0.39; I(2) = 0%). Acotiamide showed a significantly beneficial effect on the elimination of some individual FD symptoms compared with placebo. Adverse events were not significantly different between acotiamide and placebo groups. Subgroup analyses suggested that acotiamide 100 mg three times daily (tid) showed consistent efficacy not only for the overall improvement but also for the elimination of some individual symptoms in FD patients.
  
  
  CONCLUSIONS
  Acotiamide has the potential to improve the symptoms of patients with FD, particularly of patients with PDS, without major adverse effects. The dosage of acotiamide 100 mg tid might be the appropriate dose in the treatment of FD.
authors.affiliation: Department of Pediatrics, West China Second Hospital, Sichuan University, No. 20, Section 3, Renmin Nanlu, Chengdu, Sichuan 610041, China.
authors.forename: Guoguang
authors.identifier: 0000-0002-0535-6642
authors.initials: G
authors.lastname: Xiao
authors.affiliation: Department of Pediatrics, The Medical Center of Dujiangyan, Chengdu 611830, China.
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Xie
authors.affiliation: Department of Pediatrics, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu 610072, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Fan
authors.affiliation: Department of Pediatrics, West China Second Hospital, Sichuan University, No. 20, Section 3, Renmin Nanlu, Chengdu, Sichuan 610041, China.
authors.forename: Jianjun
authors.initials: J
authors.lastname: Deng
authors.affiliation: Department of Pediatrics, West China Second Hospital, Sichuan University, No. 20, Section 3, Renmin Nanlu, Chengdu, Sichuan 610041, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Tan
authors.affiliation: Department of Pediatrics, West China Second Hospital, Sichuan University, No. 20, Section 3, Renmin Nanlu, Chengdu, Sichuan 610041, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Department of Pediatrics, West China Second Hospital, Sichuan University, No. 20, Section 3, Renmin Nanlu, Chengdu, Sichuan 610041, China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Guo
authors.affiliation: Department of Pediatrics, West China Second Hospital, Sichuan University, No. 20, Section 3, Renmin Nanlu, Chengdu, Sichuan 610041, China.
authors.forename: Chaomin
authors.identifier: 0000-0003-1480-3050
authors.initials: C
authors.lastname: Wan
mesh_terms: D001549:Benzamides / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004415:Dyspepsia / Q000188:drug therapy*; D006801:Humans; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D001549:Benzamides; D013844:Thiazoles; C410959:Z 338